Theraclion

Theraclion's mission is to disrupt invasive surgery through its proprietary robotic HIFU (echotherapy) platform, enabling precise, non-invasive tissue ablation. The company has achieved commercial traction with its SONOVEIN system for varicose veins, supported by CE Mark and FDA-pivotal trial data, and is expanding its geographic footprint. Its strategy focuses on dominating the non-invasive venous treatment segment while leveraging its adaptable platform for future indications in oncology and beyond.

Proprietary robotic platform combining High-Intensity Focused Ultrasound (HIFU) for thermal ablation with real-time ultrasound imaging, enabling precise, non-invasive, office-based surgical procedures.

In varicose veins, Theraclion faces established catheter-based thermal (laser/RF) and non-thermal (glue, MOCA) ablation techniques, competing on its unique fully non-invasive value proposition. In benign tumors, it competes with surgery and needle-based ablation techniques, differentiating through its non-invasive, scarless approach and tissue preservation.